Understanding the role of Mettl3, DDX23, m6A modification, and the PI3K/Akt pathway in gemcitabine resistance provides insights into potential avenues for overcoming this treatment obstacle in pancreatic cancer. Here, AKT1 is linked to familial pancreatic carcinoma.